The avian Rev-T retrovirus encodes the oncoprotein v-Rel, a member of the Rel/nuclear factor (NF)-jB transcription factor family. The aggressive oncogenic potential of v-Rel has arisen from multiple mutations within the coding sequence of the avian cellular protein c-Rel. In this study, using quantitative biochemical experiments, we have tested the role of a limited set of alterations between v-Rel and c-Rel located within the Rel homology region (RHR) of the family that might confer functional differences. Our results show that only a set of six mutations within the RHR of v-Rel are responsible for its ability to bind to a broad spectrum of jB-DNA that are normally regulated by distinct NF-jB dimers. We also observe that both v-Rel homodimer and p50/v-Rel heterodimer bind IjBa weakly compared to other cellular Rel/NF-jB dimers with transcription activation potential. We suggest that the ability of v-Rel homodimer to deregulate subunit-specific gene expression and its ability to evade IjB inhibition are crucial to its strong oncogenic potential.
Introduction
The Rel/nuclear factor (NF)-kB family of transcription factors are key regulators of the innate and adaptive immune response as well as other cellular activities including growth, differentiation, and apoptosis. The mammalian Rel/NF-kB family is composed of five proteins p50 (NF-kB1), p52 (NF-kB2), p65 (RelA), c-Rel, and RelB that are active as homo-and heterodimers (Baeuerle and Henkel, 1994; Baeuerle and Baltimore, 1996; Baldwin, 1996; Ghosh et al., 1998) . All family members contain an approximately 300 amino-acid region of high homology known as the Rel homology region (RHR). The RHR contains all of the residues necessary for dimerization, DNA-binding, nuclear localization, and inhibitor binding (Siebenlist et al., 1994; Perkins, 1997) .
In uninduced cells Rel/NF-kB dimers that contain transcription activation domains, such as homo-and heterodimers of p65 and c-Rel, are held inactive by members of the inhibitor of kB (IkB) family of proteins. The most abundant of the IkB proteins across most cell types is IkBa. The X-ray structures of IkB/NF-kB complexes have revealed the inhibitory mechanism in atomic detail Jacobs and Harrison, 1998) . These structures show that IkB binds primarily to a segment of roughly 30 amino-acid residues that contains the nuclear localization sequence (NLS) and residues immediately downstream of the NLS of the NF-kB dimers. Upon induction, IkBs are removed through a ubiquitin-linked proteosome degradation pathway, allowing free NF-kB to translocate to the nucleus to bind to target DNA sequences in gene enhancers (called kB sites), and activate transcription.
There are three broadly defined classes of kB DNA sites, based on their length and the ability to bind distinct NF-kB dimers. All kB sites consist of two half sites of either 5 bp (bound by p50 and p52 monomers) with a 5 0 -GGGRN-3 0 consensus or 4 bp 5 0 -GGAA-3 0 half sites (bound by p65 and c-Rel monomers). These half-sites are separated by a 1 bp spacer. The size of the kB site bound by a specific dimer is size of the monomer one half-site plus the 1 bp spacer plus the monomer two half-site (1/2-site þ 1 þ 1/2-site). These preferences has been determined based on the DNA specificity observed in the crystal structures of NF-kB dimer/DNA complexes (Ghosh et al., 1995; Muller et al., 1995; Cramer et al., 1997; Chen et al., 1998a Chen et al., , b, 2000b Berkowitz et al., 2002) . The classes of kB sites are 11 bp sites bound by p50 and p52 homodimers (5 þ 1 þ 5), 10 bp sites bound by heteordimers of p50 and either p65 or c-Rel (5 þ 1 þ 4), and 9 bp sites bound by homodimers of p65 and c-Rel and p65/c-Rel heterodimers (4 þ 1 þ 4) (Chen and Ghosh, 1999; Huang et al., 2001) . The first Rel/NF-kB protein isolated was the avian oncoprotein v-Rel from the reticuloendotheliosis virus (REV) (Theilen et al., 1966) . v-Rel is a potent oncogene in birds, producing multiple lymphomas within a few days of infection. The cellular homolog of v-Rel is the proto-oncogene crel . The c-Rel protein itself is transforming when expressed from a viral promoter, but it is not nearly as potent as v-Rel. Although not occurring in mammals, v-Rel expression in transgenic mice produces lymphomas and leukemias as well (Carrasco et al., 1996) .
There are four main differences between c- v-Rel (Hannink and Temin, 1989, 1990; Capobianco et al., 1990; Gilmore, 1999) . First, the last 118 amino acids of c-Rel's transactivation domain are truncated in v-Rel. Second, six amino acids are mutated and four others are deleted in the remaining C-terminal activation domain of v-Rel. Third, there are 11 amino acids at the N-terminal and 18 amino acids at the C-terminal of v-Rel from the REV env gene. These additional amino acids are out of frame with the env gene itself. Finally, there are seven single residue differences within the RHR itself (Figure 1 ). Of these, five residues are within the DNA-binding region, although none of them are in positions that directly contact DNA. The remaining two mutations (Tyr286Ser and Leu302Pro) are at positions that are involved in IkBa binding, as observed in the p65/p50/IkBa structures Jacobs and Harrison, 1998) . Figure 2 shows the locations of mutated residues of v-Rel RHR in comparison to the analogous residues in chicken c-Rel.
v-Rel transformation in mice is correlated with overexpression of kB-regulated genes (Carrasco et al., 1996) . Also, DNA binding is required for v-Relmediated transformation in both birds and mammals (Kumar et al., 1992; Morrison et al., 1992; White and Gilmore, 1993) . In transformed cells, a pool of v-Rel is constitutively nuclear, as it is able to avoid regulation by IkB proteins (Gilmore and Temin, 1986; Hrdlickova et al., 1995) . The nuclear v-Rel presumably binds to kB DNA in the enhancers of genes that are not regulated by its cellular counterpart c-Rel. The oncogenic mutations within the RHR (Figure 1 ) are responsible for the altered DNA-binding specificity observed in v-Rel (Nehyba et al., 1997) .
In order to better understand the molecular mechanism behind how the differences in the RHRs of c-Rel and v-Rel lead to v-Rel's potent oncogenicity, we have formed v-Rel and c-Rel homodimers, as well as their heterodimers with p50, and tested the ability of these dimers to bind different physiologic kB sites from several genes including those that are known to promote proliferation and inhibit apoptosis. We have also quantified and compared the affinities of c-Rel and v-Rel with IkBa to determine how IkBa interaction determines the cellular partitioning of v-Rel.
Results

v-Rel and c-Rel exhibit disparate DNA recognition properties
We have used a fluorescence anisotropy assay (FAA) (Phelps et al., 2000b) to determine the affinities of v-Rel and c-Rel for four different kB sites. These sites belong to two classes of kB DNA; 9 bp kB-like sites that are known to bind c-Rel and p65 homodimers and 10 bp kB-sites specific for p50 homo-and heterodimers. The sites assayed were from the IL2 and IL8 enhancers, 9 bp, and the Ig/HIV and IFNb enhancers, 10 bp (sequences in Materials and methods). Sample binding curves from the FAAs for v-Rel on the kB targets are shown in Figure 3 . As shown in Table 1 and Figure 4 , v-Rel is capable of recognizing the four kB sites with similar affinities (K D B60 nM). The only exception was the 9 bp IL8 target site, which v-Rel bound with two-fold less affinity (K D , 118 nM). The kB DNA affinity of c-Rel and v-Rel are only the same for the IL2 CD28RE, which is also the only nonstandard kB site used in these assays. The first half-site sequence is AGAA rather than the consensus GGAA. c-Rel, on the other hand, clearly discriminates against the 10 bp kB sites, binding them with 4-8-fold lower affinity than the 9 bp IL2 and IL8 kB targets. These results suggest that a small set of mutations within the DNA-binding domain, located at positions removed from the DNA-protein interface, can play a major role in discriminating DNA targets.
We have also tested if c-Rel from human and chicken differ in DNA-binding specificity. Their affinities for two DNA targets, one each from the two classes (IL2 -9 bp and Ig/HIV -10 bp) were determined. Human c-Rel shows the same DNA binding pattern as chicken c-Rel (Table 1) . This is striking because human and chicken c-Rel differ at 43 positions, spread throughout the DNA-binding RHR, while v-Rel differs from chicken c-Rel at only 10 positions and possesses an entirely different binding pattern.
Effect of v-Rel mutations on DNA binding
The N-terminal env residues fused to the RHR of v-Rel has been shown to significantly contribute to its oncogenic potency (Epinat et al., 2000a, b) . These residues are derived from viral env protein with three mutations. Although this segment has been recently shown to participate in transcriptional activation function, we wanted to see if it plays an additional role in DNA-binding specificity. Therefore, we also tested jB binding by c-Rel and v-Rel CB Phelps and G Ghosh binding to 9 (IL2) and 10 (Ig/HIV) bp sites by a longer v-Rel construct (1-320) that included the env-derived residues. Our results revealed that this N-terminal segment has no effect on v-Rel's DNA-binding properties (Table 1) . The average binding is in fact slightly weaker, showing that the additional amino-terminal residues of v-Rel do not contribute to DNA binding. Therefore, differences in DNA binding between v-Rel and c-Rel are a result of the mutations within the RHR itself.
We wanted to determine how the oncogenic mutations within the RHR affect DNA binding. The five mutations (from c-Rel to v-Rel) within the RHR shown to contribute to altered binding in vivo are Met20Thr, Asp82Gly, Arg97Gln, Arg250Gly, and Glu269Ala (Nehyba et al., 1997) . Of these five mutations, only Met20Thr and Glu269Ala are conserved across the Rel/ NF-kB family and are located in proximity to the protein-DNA interface in the c-Rel/IL-2 kB DNA complex ( Figure 2a ). The other three mutations are all at locations distant from the interface. Therefore, we speculated that these two mutations were most likely the cause of altered DNA-binding specificity by v-Rel. To determine this, we reversed these mutations in v-Rel back to c-Rel-specific residues (Thr29Met and Ala278-Glu) both singly and in combination. Single mutations have no effect on v-Rel DNA binding (Table 2 , Figure 4b ). The double mutant did alter v-Rel's DNA binding, but instead of converting it to c-Rel-like specificity, the double mutant decreased v-Rel's binding to all four target kB sites by approximately twofold. These observations lead us to believe that other v-Relspecific residues also play a role in altered DNA-binding specificity of v-Rel.
p50/c-Rel and p50/v-Rel exhibit identical DNA-binding properties
In addition to functions as homodimers, both c-Rel and v-Rel are known to heterodimerize with p50. To understand how p50/v-Rel heterodimer binds kB DNA sequences relative to the p50/c-Rel, first we needed to form these two heterodimers. In the process of making these heterodimers, we noticed that p50 more efficiently heterodimerizes with c-Rel compared to v-Rel. Whereas both p50/p65 and p50/c-Rel heterodimers can be formed by simply mixing the components at appropriate concentrations, this procedure was not sufficient to form the p50/v-Rel heterodimer with high efficiency. Instead, v-Rel had to be unfolded and refolded in the presence of p50 for effective heterodimer formation. We also observed that higher molar ratio of v-Rel relative to p50 was required for the formation of p50/v-Rel heterodimer. In the case of c-Rel, p65, and p50, the homodimers are sufficiently weaker than the heterodimer The sequences of the kB sites tested are: IL2 CD28RE -AGAAATTCC, IL8 -GGAATTTCC, Ig/HIV -GGGACTTTCC, and IFNb-GGGAAATTCC. For all experiments, the RHR of the proteins were used, except for experiments that included the 11 amino-terminal env residues of v-Rel 1-320 (v-Rel+env residues) We have measured the affinities of both of these heterodimers for the four kB DNA sequences mentioned above. Surprisingly, these heterodimers have an identical binding pattern for the two classes tested here. Table 1 and Figure 4a show their relative DNA-binding affinity. Together these observations suggest that the v-Rel homodimer is able to deregulate normal physiology by activating genes that would not otherwise be responsive for its cellular counterpart, c-Rel.
v-Rel binds to kB sites not physiologically regulated by c-Rel
We wanted to further test the binding potency of v-Rel to kB DNA that are present in the regulatory regions of genes known to be involved in cellular proliferation and inhibition of programmed cell death. The regulation of these genes are normally mediated by NF-kB heterodimers. These sites are from the enhancers of the antiapoptotic and proliferative genes Bcl-x(L), the interferon responsive factor 4 (IRF4), and c-myc (Duyao et al., 1990; Tsukahara et al., 1999; Grumont and Gerondakis, 2000) . Although all three sites belong to the 10 bp heterodimer class of kB sites, these sequences deviate somewhat from the consensus sequence for p50/p65 heterodimer binding. Binding was analysed by fluorescence anisotropy competition assays using unlabeled Bcl-x(L), IRF4, and c-myc DNA, with IL2 CD28RE as the labeled probe. The IL2 CD28RE was chosen because all four dimers have the same affinity for this site (Table 1) .
Our results show that the p50/c-Rel heterodimer bound tightest followed closely by v-Rel homodimer and p50/v-Rel heterodimer. The competitor DNAs inhibited c-Rel binding to the IL2 CD28RE probe much more weakly (4-7-fold) than the other dimers (Table 3) . These results confirm that v-Rel containing dimers can also bind tightly to kB sites normally regulated by the p50/c-Rel heterodimer.
c-Rel binds IkBa through the same mechanism as p65
Crystal structures, direct binding assays, and protease sensitivity assays of p65/IkBa complexes have shown that IkBa recognizes only one of the two NLSs in the Rel/NF-kB dimer, whereas the other NLS is exposed to the solvent (Huxford et al., , 2000 Jacobs and Harrison, 1998; Phelps et al., 2000a) . To test if c-Rel binds to IkBa similarly, primarily through interaction with one NLS, we have carried out protease sensitivity experiments of c-Rel, p65, and v-Rel complexed to IkBa and compared them to the free Rel/NF-kB dimers ( Figure 5 ). We observe that a stable doublet is formed within few minutes and persists over a long time for both p65 and c-Rel. In case of p65/IkBa, we analysed the doublet and found that the bottom band corresponds to a p65 subunit without the NLS and the top band corresponds to a p65 subunit containing the NLS. As with p65, only one c-Rel NLS is protected by IkBa. Our results thus confirm that the general mode of binding of IkBa to p65 and c-Rel is similar. In contrast to c-Rel, v-Rel homodimer is insensitive to thermolysin digestion. Therefore, it is difficult to determine if IkBa protects either NLS of v-Rel.
IkBa binds c-Rel and v-Rel with different affinities
To gain information of how IkBa inhibits v-Rel compared to cellular NF-kB dimers, we have tested IkBa for its ability to inhibit DNA binding of v-Rel and The sequences of the kB sites tested are: IL2 CD28RE -AGAAATTCC, IL8 -GGAATTTCC, Ig/HIV -GGGACTTTCC, and IFNb-GGGAAATTCC. All assays were performed using the RHR portion of v-Rel (amino acids 16-291) Extended c-Rel and v-Rel constructs, 1-311 and 1-320, respectively, were used for the competition assays as previous work with p65 had shown that the B20 amino acids C-terminal to the NLS were necessary for full IkBa binding (Phelps et al., 2000a) . Figure 6 shows a comparison of the inhibition curves for p65, c-Rel, v-Rel, and p50/v-Rel. IkBa is a much better inhibitor of p65 homodimer and the c-Rel homo-and heterodimers than v-Rel homo-or heterodimer (seven-and four-fold, respectively, Table 4 ). Since the thermolysin proteolysis assay was unable to assess the role of the v-Rel NLS in the interaction with IkBa, we also tested v-RelNLS(16-291) for its ability to bind IkBa. The inhibition (K I 404.2711.8 nM) was only slightly weaker than that of v-Rel 1-320 . This indicates that the NLS-containing region of v-Rel is marginally involved in binding to IkBa, as suggested previously (Sachdev and Hannink, 1998) . Similar results have been observed with the p50 homodimer binding to IkBa as well (Phelps et al., 2000a) . Complexes of IkBa with NFkB dimers containing p50 shuttle between the nucleus and cytoplasm (Malek et al., 2001 ) like v-Rel/IkBa complexes.
This data also confirms our previous observations on the ability of IkBa to inhibit p65 DNA binding. IkBa inhibition of p65 binding to the IL2 kB DNA (Table 4) is similar to its inhibition of p65 binding to Ig/HIV kB DNA .
As IkBa is constitutively phosphorylated by Casein Kinase II in vivo (Barroga et al., 1995; McElhinny et al., 1996) , we also tested the effects of this phosphorylation on IkBa-mediated inihibition of p65, c-Rel, and v-Rel. The phosphorylation of IkBa increased inhibition of p65 by five-fold, consistent with previous direct binding assays (Phelps et al., 2000a) . A similar improvement of binding affinity was also observed with c-Rel. Although phosphorylation did improve IkBa inhibition of v-Rel, the effect was not as drastic as for p65 and c-Rel. As a result, phosphorylated IkBa, binding to p65 and c-Rel is 14-and eight-fold tighter, respectively, compared to v-Rel (Table 4) .
Discussion
The v-Rel oncogene is a transcription factor of the Rel/ NF-kB family. Like all transcription factors it must bring its activation domain into the proximity of the promoter through binding to sites in gene enhancers. Part of v-Rel's oncogenicity is conferred by its altered transactivation domain (Chen et al., 1999a; Gilmore, 1999) and the enhanced transactivation potential conveyed by the env residues inserted at its N-terminus (Epinat et al., 2000a (Epinat et al., , 2000b . Research by others has shown that specific differences between the v-Rel and c-Rel activation domains, as well as their post-translational modification are important for v-Rel's activity. Additionally, the transforming potential of v-Rel is directly correlated with its transactivation potential (Rayet et al., 2003) . However, before v-Rel can bring its activation domain into play it must first localize to the nucleus and bind to the kB sites in the genes' enhancers. Previous experiments have suggested that v-Rel exhibits differential nuclear translocation and DNA binding compared to its cellular counterpart c-Rel. In this report, we have undertaken a quantitative biochemical analysis of the differences between c-Rel and v-Rel binding to IkBa and kB DNA and explained the results in the context of available crystallographic models.
We observed that v-Rel homodimers and p50/v-Rel heterodimers are weakly inhibited by IkBa, the most common IkB, compared to the classical NF-kB targets of IkBa (p65 and c-Rel). Both unmodified and PESTphosphorylated IkBa exhibit a similar pattern of inhibition. The two mutations in the vicinity of the v-Rel NLS (Figures 1 and 2b) are the most likely cause of the decreased binding affinity. It is known that the NLS of v-Rel does not contact IkBa (Sachdev and Hannink, 1998) . However, the role of these mutations is not to prevent direct contacts between the v-Rel NLS and IkBa, but instead to disrupt the contacts between IkBa and the region C-terminal to the NLS that is responsible for high-affinity binding in p65 and c-Rel complexes with IkBa. The p65 and c-Rel homodimers show asymmetric binding to IkBa, with only one of the NLSs masked. Previous results have shown that, like v-Rel/IkBa complexes, other NF-kB dimers in complex with IkBa shuttle between the nucleus and the cytoplasm (Malek et al., 2001; Tam et al., 2001) . The difference between these complexes and v-Rel/IkBa is that the standard NF-kB/IkBa complexes are entirely cytoplasmic in the steady state, while a portion of v-Rel is capable of localizing in the nucleus for prolonged periods of time.
The affinity of physiologically relevant, phosphorylated IkBa for v-Rel is still reasonably tight, the K I is approximately 80 nM. However, it is not simply the affinity of the two proteins that determines the fraction found in complex, but both affinity and the relative abundance of the complex components. In this case, there is simply not enough IkBa present in cells to block all of the cellular NF-kBs and v-Rel simultaneously. Indeed, IkBa and v-Rel are known to associate in vivo. In v-Rel-transformed cells the majority of v-Rel is found sequestered in the cytoplasm bound to IkBa (Gilmore and Temin, 1986) . Despite this association, up to 30% of the cellular v-Rel is found in the nucleus and there appears to be a threshold level of nuclear v-Rel required for transformation (Sachdev et al., 1997) . That the distribution of v-Rel and v-Rel/IkBa in cells is an equilibrium event is further reinforced by the observation that overexpression of IkBa in REV-infected cells decreases the transforming potential of v-Rel and results in v-Rel's complete sequestration in the cytoplasm (Hrdlickova et al., 1995) . Also, the ikba gene is known to be under NF-kB control, normally the p50/c-Rel and p50/p65 heterodimers (Cheng et al., 1994) . Despite v-Rel's broader DNA specificity, it is a much weaker inducer of ikba than other NF-kB dimers, resulting in only a slight increase in IkBa expression in v-Reltransformed cells (Schatzle et al., 1995) .
Once v-Rel has evaded IkB regulation it must then bind to kB DNA target sites in order to bring about the altered gene expression observed in REV-infected cells. Here, we have tested two major classes of kB sites for their potential to bind c-Rel and v-Rel. Although kB sites are separated into two main classes, the 9 and 10 bp sites, which are differentially recognized by c-Rel homodimers, we still observe variations in DNA affinity for c-Rel within each class. Our results clearly reveal a distinct pattern for c-Rel binding to these target sites. c-Rel prefers 9-bp targets, and coincidently, these target sites are located within the promoters of cytokines and interleukins. In addition, most of these 9-bp targets have identical or very similar sequences to the IL8-kB site or the IL2 CD28RE. It is known that c-Rel is a transcription factor of profound importance in the proliferation and differentiation of lymphoid cells (Li and Verma, 2002) . In contrast to c-Rel, v-Rel binds all four sequences and both classes with equal affinity. This clearly suggests that nuclear v-Rel will bind to kB sites that would not be otherwise regulated by c-Rel. A number of key factors expressed in response to v-Rel and important for transformation are the antiapoptotic proteins Bcl-2, Bcl-x(L), and c-IAP, cell proliferation promoter c-myc, as well as other transcription factors such as AP1, the high-mobility group protein 14, and IRF-4 (Walker and Enrietto, 1996; You et al., 1997; Kralova et al., 1998; Chen et al., 2000a; Hrdlickova et al., 2001; Heckman et al., 2002) . The p50/c-Rel heterodimer appears to regulate the expression of these genes. We find that the v-Rel homodimer and p50/v-Rel heterodimer are almost equally potent in recognizing these sites, suggesting that v-Rel can regulate the expression of a broad spectrum of genes that are normally regulated by distinct subclasses of NF-kB dimers.
It is well known that v-Rel forms heterodimers by associating with other members of the NF-kB family (Davis et al., 1990; Capobianco et al., 1992) . Although, no study has been done to determine the relative strengths of these dimers, we have noticed, during the process of forming the p50/v-Rel heterodimer, that the p50/v-Rel heterodimer may not be much stronger than the v-Rel homodimer. In contrast, we see that p50/c-Rel is a more stable heterodimer than the homodimers of the individual subunits. Similarly, p50/p65 heterodimer is more stable than the p50 and p65 homodimers. These conclusions are primarily based on the efficiencies of the heterodimer formation by the unfolding-refolding process. Interestingly, we observe that the DNA-binding properties of v-Rel homodimer and v-Rel/p50 heterodimer are almost identical irrespective of the nature of DNA. It thus appears that the broadened DNA-binding capacity of the homodimer makes it more oncogenic, as it can carry out its transcriptional function without requiring any other member of the family. We suggest that the v-Rel homodimer is most likely the main factor in the unregulated expression of Rel/NF-kB-controlled genes. Our result is consistent with recent reports which show that transformation requires threshold levels of nuclear v-Rel homodimer. Mutant v-Rel that could form heterodimers, but not homodimers, were unable to transform cells in vitro (Liss and Bose, 2002) .
Our original hypothesis was that v-Rel followed a different set of rules in DNA binding because of the mutations in the RHR close to the DNA-binding interface (T29 and A278). Binding experiments on mutant v-Rel dimers with the corresponding c-Rel residues (M and E, respectively) revealed that mutation of these residues is unable to confer c-Rel-like specificity on v-Rel. The other mutations, distant from the DNAbinding interface must therefore also play a role in altering v-Rel's DNA specificity. The role of these distal mutations remains to be determined, as well as how they cooperate with the T29 and A278 residues to alter v-Rel's activity.
Constitutive expression of NF-kB dimers has been shown to be critical for several human tumors of hematopoietic origin. In all cases NF-kB plays two different roles, both of which promote tumorigenesis; it helps cell proliferation and inhibits cell death by upregulating factors that are directly involved in these two processes (Bharti and Aggarwal, 2002) . v-Rel, the virally encoded, oncogenic member of the family, when present in cells, creates a state similar to constitutively nuclear NF-kB. Although our knowledge of which of these genes are expressed early in viral infection is limited, data reveals that v-Rel regulates both antiapoptotic factors such as ch-IAP and Bcl-2/xL, and proliferative genes such as myc and cyclins (Petrenko et al., 1997; You et al., 1997) . Constitutively nuclear v-Rel not only enhances gene expression in an untimely fashion, it also disturbs the specificity in the gene expression that is finely tuned within the NF-kB family members. Our results clearly show at least two of the steps that lead to this v-Rel-mediated aberrant gene expression.
Materials and methods
Cloning, expression, and purification
All c-Rel (G. gallus 7-281 and Homo sapiens 1-311) and v-Rel constructs (16-291 and 1-320) were cloned into T7 promoter driven Escherichia coli expression vectors (pET11a or pET15b, Novagen). The proteins were expressed in BL21[DE3] E. coli cells. Proteins cloned into pET11a were purified by cationexchange chromatography (SP-sepharose, Amersham Biosciences) followed by size exclusion (Superdex 200, Amersham Biosciences). Proteins cloned into pET15b were purified on Ni 2 þ -affinity resin (ProBond, Novagen) followed by Superdex 200 size exclusion. The c-Rel/p50 and v-Rel/p50 heterodimers were prepared from purified c-Rel, v-Rel, and p50 by refolding according to published protocols (Chen et al., 1999b) . v-Rel mutants were prepared using a Quick Change PCR mutagenesis kit (Stratagene) using v-Rel The v-Rel mutants were purified as above.
Full-length (1-317) and DSRRDC (67-302) IkBa were expressed and purified following the previously reported protocols (Huxford et al., 2000; Phelps et al., 2000a) . All probes were annealed to unlabeled complementary strands prior to use. c-Rel and v-Rel dimers were then serially diluted into 0.5 ml binding reactions. After the dilutions, each tube was blanked and the labeled oligonucleotides were added at constant concentration (0.2 nM). The reactions were equilibrated for 40 min prior to measurement. Equilibrium binding constants were calculated by the concentration of protein at which half of the DNA probe is bound. FAA competition assays using full-length IkBa were carried out and the K I was calculated according to Malek et al. (1998) . Competition assays using competitive kB sites were carried out in a similar manner to the IkBa assays using 18 mer duplex DNAs containing the kB sites from the IRF4, Bcl-x(L), and cmyc enhancers (Duyao et al., 1990; Tsukahara et al., 1999; Grumont and Gerondakis, 2000) ; IRF4: 5 0 -CTCAGG GATCCCCCATCT-3 0 , Bcl-x(L): 5 0 -ATAAAGGGACTTC CAAGA-3 0 , c-myc: 5 0 -GTCCGGGTTTTCCCCAAC-3 0 . All competition reactions were carried out at constant Rel and DNA concentrations of 200-400 and 10 nM, respectively.
Thermolysin protection assay
Equimolar amounts of either p65 (RelA) or c-Rel were combined with IkBa 67-302 and allowed to equilibrate for 30 min, prior to the addition of Thermolysin protease (Boerhinger Mannheim). The reactions were carried out at room temperature in a buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM DTT, 2 mM CaCl 2 , and 0.15 mM ZnSO 4 using 400 mg of Rel/IkBa complex or 200 mg Rel only controls. Thermolysin was added to the target proteins in a 1 : 200 ratio by mass (2 or 1 mg, respectively). The reactions were quenched by the addition of 8 ml of reaction to 1 ml of 0.5 M EDTA (pH 8.0) and 3 ml of 4Â SDS sample dye followed by incubation at 1001C for 2 min, prior to analysis by 15% SDS-PAGE.
